Clinical Factors Predict Atezolizumab Response.

abstract：:Mutating a conserved motif in the activation loop of MEC1 (ATR) revealed the activation mechanism. ...

journal_title：Cancer discovery

authors：

更新日期：2020-11-20 00:00:00

abstract：:Results from a phase III trial indicate that maintenance therapy with the PARP inhibitor niraparib is more effective than placebo in slowing the progression of recurrent platinum-sensitive ovarian cancer. Improved progression-free survival was seen regardless of the presence or absence of germline BRCA mutations, or o...

journal_title：Cancer discovery

authors：

更新日期：2016-12-01 00:00:00

abstract：:A phase II study indicates that sacituzumab govitecan (IMMU-132), a Trop-2-specific antibody linked to the irinotecan metabolite SN-38, prolongs the progression-free survival of patients with advanced triple-negative breast cancer. IMMU-132 is well tolerated, causing fewer and more manageable side effects than irinote...

journal_title：Cancer discovery

authors：

更新日期：2016-01-01 00:00:00

abstract：:Metabolic reprogramming enables cancer cell growth, proliferation, and survival. This reprogramming is driven by the combined actions of oncogenic alterations in cancer cells and host cell factors acting on cancer cells in the tumor microenvironment. Cancer cell intrinsic mechanisms activate signal transduction compon...

journal_title：Cancer discovery

authors： Dey P,Kimmelman AC,DePinho RA

更新日期：2021-01-27 00:00:00

abstract：:The NCI and Department of Veterans Affairs (VA) are collaborating on the NCI and VA Interagency Group to Accelerate Trials Enrollment, or NAVIGATE, which will launch at 12 VA facilities across the country. The program aims to increase participation of veterans with cancer in NCI-sponsored clinical trials. ...

journal_title：Cancer discovery

authors：

更新日期：2018-08-01 00:00:00

abstract：:The Ivy Glioblastoma Atlas provides detailed information about genes expressed in different anatomic regions of human brain tumors. Researchers are already drawing upon the resource to identify novel therapeutic targets for this deadly cancer. ...

journal_title：Cancer discovery

authors：

更新日期：2018-07-01 00:00:00

abstract：UNLABELLED:Although disordered chromatin organization has long been recognized as a feature of cancer, the molecular underpinnings of chromatin structure, epigenetic regulation, and their relationships to transcription are only beginning to be understood. Cancer genome sequencing studies have revealed a novel theme: fr...

journal_title：Cancer discovery

authors： Wu JN,Roberts CW

更新日期：2013-01-01 00:00:00

abstract：:A new study of all 32 cancer types in The Cancer Genome Atlas identifies genomic alterations that increase the activity of the PI3K/AKT/mTOR pathway. The study, which combines mutation data with measures of protein levels and phosphorylation status, suggests that mutations in IDH1, VHL, and STK11 promote activation of...

journal_title：Cancer discovery

authors：

更新日期：2017-08-01 00:00:00

abstract：UNLABELLED:Genetic approaches have shown that the p110β isoform of class Ia phosphatidylinositol-3-kinase (PI3K) is essential for the growth of PTEN-null tumors. Thus, it is desirable to develop p110β-specific inhibitors for cancer therapy. Using a panel of PI3K isoform-specific cellular assays, we screened a collectio...

journal_title：Cancer discovery

authors： Ni J,Liu Q,Xie S,Carlson C,Von T,Vogel K,Riddle S,Benes C,Eck M,Roberts T,Gray N,Zhao J

更新日期：2012-05-01 00:00:00

abstract：:Kidney cancer is not a single disease but represents several distinct types of cancer that have defining histologies and genetic alterations and that follow different clinical courses and have different responses to therapy. Mutation of genes associated with kidney cancer, such as VHL, FLCN, TFE3, FH, or SDHB, dysregu...

journal_title：Cancer discovery

authors： Linehan WM,Schmidt LS,Crooks DR,Wei D,Srinivasan R,Lang M,Ricketts CJ

更新日期：2019-08-01 00:00:00

abstract：:In the large international phase III MAVORIC trial, patients with previously treated cutaneous T-cell lymphoma who received the anti-CCR4 monoclonal antibody mogamulizumab experienced significantly longer progression-free survival and higher response rates, as well as better quality of life, than those who received vo...

journal_title：Cancer discovery

authors：

更新日期：2018-02-01 00:00:00

abstract：UNLABELLED:Knowledge of "actionable" somatic genomic alterations present in each tumor (e.g., point mutations, small insertions/deletions, and copy-number alterations that direct therapeutic options) should facilitate individualized approaches to cancer treatment. However, clinical implementation of systematic genomic ...

journal_title：Cancer discovery

authors： Wagle N,Berger MF,Davis MJ,Blumenstiel B,Defelice M,Pochanard P,Ducar M,Van Hummelen P,Macconaill LE,Hahn WC,Meyerson M,Gabriel SB,Garraway LA

更新日期：2012-01-01 00:00:00

abstract：:A recent study investigated the mechanisms underlying the interaction between olaparib and cediranib in non-BRCA-mutant ovarian cancer. Cediranib may confer sensitivity to olaparib by increasing tumor hypoxia and inhibiting platelet-derived growth factor receptor, which reduces BRCA1/2 and RAD51 expression, thus decre...

journal_title：Cancer discovery

authors：

更新日期：2019-08-01 00:00:00

abstract：:Agonistic antibodies targeting CD137 have been clinically unsuccessful due to systemic toxicity. Because conferring tumor selectivity through tumor-associated antigen limits its clinical use to cancers that highly express such antigens, we exploited extracellular adenosine triphosphate (exATP), which is a hallmark of ...

journal_title：Cancer discovery

authors： Kamata-Sakurai M,Narita Y,Hori Y,Nemoto T,Uchikawa R,Honda M,Hironiwa N,Taniguchi K,Shida-Kawazoe M,Metsugi S,Miyazaki T,Wada NA,Ohte Y,Shimizu S,Mikami H,Tachibana T,Ono N,Adachi K,Sakiyama T,Matsushita T,Kadono

更新日期：2020-08-25 00:00:00

abstract：:LKB1 inactivation generates a redox imbalance that promotes ADC-to-SCC transdifferentiation in NSCLC. ...

journal_title：Cancer discovery

authors：

更新日期：2015-07-01 00:00:00

abstract：:Nuclear hormone receptor targeting suppresses melanoma progression in diverse preclinical models. ...

journal_title：Cancer discovery

authors：

更新日期：2014-05-01 00:00:00

abstract：UNLABELLED:B-cell lymphomas frequently contain genomic rearrangements that lead to oncogene activation by heterologous distal regulatory elements. We used a novel approach called "pinpointing enhancer-associated rearrangements by chromatin immunoprecipitation," or PEAR-ChIP, to simultaneously map enhancer activity and ...

journal_title：Cancer discovery

authors： Ryan RJ,Drier Y,Whitton H,Cotton MJ,Kaur J,Issner R,Gillespie S,Epstein CB,Nardi V,Sohani AR,Hochberg EP,Bernstein BE

更新日期：2015-10-01 00:00:00

abstract：:CD10 and GPR77 define a cancer-associated fibroblast (CAF) subset that sustains cancer stemness. ...

journal_title：Cancer discovery

authors：

更新日期：2018-03-01 00:00:00

abstract：:IFNγ-producing NK cells induced TME remodeling and orchestrated T cell-mediated tumor control. ...

journal_title：Cancer discovery

authors：

更新日期：2020-12-04 00:00:00

abstract：:HDAC inhibitors synergize with PI3K inhibitors to reduce MYC-driven medulloblastoma (MB) growth. ...

journal_title：Cancer discovery

authors：

更新日期：2016-05-01 00:00:00

abstract：:Researchers have developed an antibody-drug conjugate with the potential to treat neuroblastoma. The agent targets ALK, which is found on neuroblastoma cells but not healthy cells, delivering a drug that causes DNA cross-links. Researchers have found that the antibody-drug conjugate kills ALK-expressing cells in vitro...

journal_title：Cancer discovery

authors：

更新日期：2019-06-01 00:00:00

abstract：:The new iRECIST guideline-developed in consultation with academics, drug companies, and regulatory authorities-provides a standardized approach to assessing whether patients' disease improves, stays the same, or worsens in trials of immunotherapeutics, agents that can trigger different response patterns from other kin...

journal_title：Cancer discovery

authors：

更新日期：2017-05-01 00:00:00

abstract：:According to results from ENZAMET, a global phase III trial, adding enzalutamide to standard treatment for men with metastatic hormone-sensitive prostate cancer is superior in prolonging survival compared with older nonsteroidal antiandrogen drugs. ...

journal_title：Cancer discovery

authors：

更新日期：2019-08-01 00:00:00

abstract：:Whether metastases were seeded mono- or polyclonally depended on cancer site and treatment. ...

journal_title：Cancer discovery

authors：

更新日期：2020-07-01 00:00:00

abstract：UNLABELLED:RNA interference (RNAi) is a potent and specific mechanism for regulating gene expression. Harnessing RNAi to silence genes involved in disease holds promise for the development of a new class of therapeutics. Delivery is key to realizing the potential of RNAi, and lipid nanoparticles (LNP) have proved effec...

journal_title：Cancer discovery

authors： Tabernero J,Shapiro GI,LoRusso PM,Cervantes A,Schwartz GK,Weiss GJ,Paz-Ares L,Cho DC,Infante JR,Alsina M,Gounder MM,Falzone R,Harrop J,White AC,Toudjarska I,Bumcrot D,Meyers RE,Hinkle G,Svrzikapa N,Hutabarat RM,Cl

更新日期：2013-04-01 00:00:00

abstract：:Adding a PI3K inhibitor to anti-estrogen receptor therapy may be a viable treatment option for women with advanced hormone receptor-positive breast cancer that becomes resistant to endocrine therapy, according to findings from the phase III BELLE-2 trial, presented at the 2015 San Antonio Breast Cancer Symposium. ...

journal_title：Cancer discovery

authors：

更新日期：2016-02-01 00:00:00

abstract：UNLABELLED:Next-generation sequencing was used to identify Notch mutations in a large collection of diverse solid tumors. NOTCH1 and NOTCH2 rearrangements leading to constitutive receptor activation were confined to triple-negative breast cancers (TNBC; 6 of 66 tumors). TNBC cell lines with NOTCH1 rearrangements associ...

journal_title：Cancer discovery

authors： Stoeck A,Lejnine S,Truong A,Pan L,Wang H,Zang C,Yuan J,Ware C,MacLean J,Garrett-Engele PW,Kluk M,Laskey J,Haines BB,Moskaluk C,Zawel L,Fawell S,Gilliland G,Zhang T,Kremer BE,Knoechel B,Bernstein BE,Pear WS,Liu

更新日期：2014-10-01 00:00:00

abstract：UNLABELLED:Glioblastomas (GBM) with EGFR amplification represent approximately 50% of newly diagnosed cases, and recent studies have revealed frequent coexistence of multiple EGFR aberrations within the same tumor, which has implications for mutation cooperation and treatment resistance. However, bulk tumor sequencing ...

journal_title：Cancer discovery

authors： Francis JM,Zhang CZ,Maire CL,Jung J,Manzo VE,Adalsteinsson VA,Homer H,Haidar S,Blumenstiel B,Pedamallu CS,Ligon AH,Love JC,Meyerson M,Ligon KL

更新日期：2014-08-01 00:00:00

abstract：:According to survival results from a phase II trial of brentuximab vedotin, 34 patients with relapsed or refractory classic Hodgkin lymphoma had a complete response with this CD30-targeting antibody-drug conjugate; 13 remain in remission 5 years later. ...

journal_title：Cancer discovery

authors：

更新日期：2016-09-01 00:00:00

abstract：:Long ignored, the importance of circadian rhythms-the focus of this year's Nobel Prize in Physiology or Medicine-is beginning to gain attention from researchers interested in cancer prevention, drug discovery, and therapeutic optimization. ...

journal_title：Cancer discovery

authors：

更新日期：2017-12-01 00:00:00